Clinical Trial Update: Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of docetaxel, oxaliplatin, and S-1 in potentially operable gastric or gastroesophageal adenocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Adenocarcinoma

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Sanofi | Conditions: Gastric Cancer | Phase 2 | Status: COMPLETED